USPTO grants MS2 Array first patent

MS2 Array is pleased to announce that on May 22, 2018 the USPTO granted the company it's first patent, US 9,977,019, "Fluorous Peptide Microarray, Detection Process Using a Fluorous Peptide Microarray, and Process of Forming a Fluorous Peptide Microarray". The issued patent claims the formation of peptide microarrays using fluorous immobilization, the reaction of the peptides, either before or after immobilization with a biomolecule of interest, then detection of the reaction products by mass spectrometry through direct ionization of the peptides from the surface.

The issuance of this patent is an important addition to the MS2 Array IP portfolio and provides validation of the novelty and utility of the technology. MS2 Array looks forward to expanding it's collection of issued patents as its other applications move forward through the examination process thereby increasing the value of the company.

MS2 Array Awarded a Phase I SBIR Grant from NIH

MS2 Array has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the NIH through the National Institute of General Medical Sciences (NIGMS). The project entitled "RNA and DNA analysis and detection by fluorous high-throughput MS" utilizes MS2 Array's technology to expand the capabilities of high-throughput mass spectrometry to the detection of RNA and DNA substrates. The Aims of the grant include optimizing protocols for nucleic acid analysis using fluorous modified MS targets, utilization of the technology for a microRNA biogenesis assay, and detection of microRNAs from cell lysates.

The work will be conducted in collaboration with Prof. Alex Deiters of the University of Pittsburgh. Prof. Deiters was one of the first researchers to report small molecule modulators of a microRNA and provides valuable expertise in microRNAs and nucleic acids and examplifies MS2 Array's commitment to working with scientific leaders.

News from SLAS 2017

High-throughput mass spectrometry as a drug discovery tool was a highlight of SLAS 2017 as it has been over the last few years. In 2013 and 2015 the SLAS Innovation Award for best presentation of the conference went to high-throughput mass spectrometry projects. This year saw important advances in HT-MALDI-MS as Bruker Daltonics continues to make instrumentation improvements to it's MALDI PharmaPulse instrument platform and recognized as the SelectScience Scientist's Choice Awardee for "Best New Drug Discovery & Development Product of 2016". At the same time AMRI announced that they had entered an alliance with Bruker Daltonics and HighRes Biosolutions in implementing HT-MALDI-MS for drug discovery. link

These developments, along with the past awards, demonstrate the appeal, importance, and potential impact of HT-MS in drug discovery. MS2 Array's technology is fully compatible with all MALDI-MS instruments and provides vital enhancements to HT-MALDI-MS such as analyte enrichment, greater sensitivity, full assay design freedom, and complete bio-orthgonality.

SLAS 2017, Feb 5th-8th

MS2 Array CEO & Co-Founder Marvin S. Yu will be attending SLAS 2017 in Washington D.C. from Sunday, Feb 5th to Wednesday, Feb 8th.

If you are also attending SLAS 2017 and would like to learn more about how we can help improve your HTS efforts then please contact Marvin at msyu@ms2array.com.